Phentolamine (OraVerse) to reverse dental numbness in children
Official title: A Randomized Effectiveness of Phentolamine Mesylate as a Reversing Agent for Local Anesthesia in Decreasing Self- Inflicted Soft Tissue Trauma Following Local Anaesthesia Injection for Dental Procedure in Children: Randomized Clinical Trial
Run by Cairo University · NCT05448807 · Data updated 2026-11-12
This tests whether OraVerse (phentolamine mesylate) can shorten the numbness children aged 5–7 experience after dental local anesthesia.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 5 Years to 7 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo, El Manial) |
| Status | Recruiting |
| Started | July 5, 2025 |
| Main results expected | April 20, 2026 |
| Study ends | June 2026 |
| Registry record updated | July 10, 2025 |
| Trial ID | NCT05448807 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy children aged 5–7 who need dental procedures with local anesthesia, have normal lip sensation and oral function before anesthesia, and can follow simple instructions are ideal candidates.
✕Probably not a fit
Children who do not receive local anesthetic with a vasoconstrictor, who do not achieve profound numbness, who cannot distinguish the numb side from the normal side, or who are unwilling to participate are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 3 interventional study at Cairo University enrolls healthy children aged 5–7 who require dental procedures with local anesthesia; after standard local anesthetic with a vasoconstrictor, participants receive phentolamine mesylate (OraVerse) to reverse soft-tissue numbness. Phentolamine is an alpha-adrenergic blocker that promotes redistribution of the anesthetic away from the injection site, which can speed the return of intraoral and perioral sensation. The protocol measures time to return of normal lip sensation and simple functional tasks (smiling, speaking, drinking) and records soft-tissue injury and adverse events. Outcomes will determine how quickly and safely oral sensation and function return after OraVerse administration.
Why it matters
Potential benefit: If successful, children could regain normal mouth sensation and function sooner, reducing accidental lip or cheek biting and post-procedure discomfort.
How similar studies have gone: Phentolamine mesylate (OraVerse) is already FDA-approved for reversing soft-tissue dental anesthesia in pediatric patients and prior studies have shown it can shorten numbness.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Children aged 5-7 years. * Patients in need of dental procedures requiring local anaesthesia. * Healthy Children without any systemic or mental disorders. * Normal lip sensation before administration of LA. * Normal paediatric functional assessment battery (pFAB) for smiling, speaking and drinking and absence of drooling. Exclusion Criteria: * Children seeking dental treatment that does not necessitate local anaesthesia. * Children who didn't achieve profound numbness requiring additional anaesthesia. * Children who lack the ability to distinct the anaesthetised numb side from the non-anaesthetised one. * Children who are not willing to participate in the study.
Where it's running
-
Cairo University
Cairo, El Manial, Egypt Recruiting
Study contacts
- Study coordinator: alaa saad abourawash
- Email: alaa.saad@dentistry.cu.edu.eg
- Phone: 01144942076
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Observational study on retained needle fragments in intravenous drug users
This study is trying to find out how common it is for people who use intravenous drugs to have leftover pieces of needles in their bodies and what factors might increase this risk.
-
68Ga-HX01 PET/CT Imaging in Soft Tissue Sarcoma patients
This study tests whether a 68Ga-HX01 injection can help PET/CT imaging better characterize soft tissue sarcoma in adults who have exhausted standard treatments or have no good options.
-
Zemetostat plus Anlotinib for SWI/SNF-deficient Head and Neck Soft Tissue Sarcoma
This trial tests whether zemetostat plus anlotinib can help people with recurrent or metastatic head-and-neck soft tissue sarcoma that has SWI/SNF complex deficiency after standard therapy fails.
-
Entinostat for pediatric soft tissue sarcoma with PAX abnormalities
This study tests entinostat, alone or with chemotherapy, in children whose soft tissue sarcomas have PAX-family gene abnormalities to see if it can help shrink tumors or slow progression.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
Preoperative Immunonutrition for bone and soft tissue sarcoma patients
This study tests whether a short course of an oral nutrition supplement before surgery can help patients with bone or soft tissue sarcomas recover better after major tumor-related surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.